Use of immunoglobulin G (IgG) concentrates with reduced anti-A and anti-B antibodies to treat neonatal jaundice caused by maternal-fetal incompatibility with ABO blood group

摘要

An embodiment relates to the use of an immonuglobulin (IgG) concentrate depleted of anti-A (AcaA) and anti-B (AcaB) antibodies for producing a drug intended for treating neonatal jaundice caused by maternal-fetal incompatibility with respect to the ABO system.